Tenpoint, Visus merge in effort to push presbyopia-correcting eye drop over FDA finish line

Tenpoint, Visus merge in effort to push presbyopia-correcting eye drop over FDA finish line

Source: 
Fierce Biotech
snippet: 

Eye-focused biotechs Tenpoint Therapeutics and Visus Therapeutics are joining forces, setting their sights on filing a new drug approval application next year for a presbyopia-correcting eye drop.